[CUSIP No. 88630M104 1. Names of reporting persons. I.R.S. Identification Nos. of above persons (entities only). 11-3694008 2. Check the appropriate box if a member of a group (see instructions) ¨ x (a) 3. SEC use only 4. Citizenship or place of organization Delaware Number of shares beneficially owned by each reporting person with: 5. Sole voting power 0 6.]
[FORM 10-Q (Mark One) x For the quarterly period ended December 31, 2013 o For the transition period from _______________ to _______________ Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of incorporation or organization) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 +0086-028-86154737 (Address, including zip code, and] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended December 31, 2013 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James Jiayuan Tong, certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended December 31, 2013 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Chief Executive Officer, Chief Accounting Officer, Chairman EX-32.1 4 f10q1213ex32i_tianyinphar.htm CERTIFICATION] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James Jiayuan Tong Chief Financial Officer, Director EX-32.2 5 f10q1213ex32ii_tianyinphar.htm CERTIFICATION]
[FORM 10-Q (Mark One) x For the quarterly period ended December 31, 2013 o For the transition period from _______________ to _______________ Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of incorporation or organization) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 +0086-028-86154737 (Address, including zip code, and] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended December 31, 2013 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James Jiayuan Tong, certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended December 31, 2013 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Chief Executive Officer, Chief Accounting Officer, Chairman EX-32.1 4 f10q1213ex32i_tianyinphar.htm CERTIFICATION] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James Jiayuan Tong Chief Financial Officer, Director EX-32.2 5 f10q1213ex32ii_tianyinphar.htm CERTIFICATION]
[for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose (Act) or otherwise subject to]
[for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose (Act) or otherwise subject to]
[SCHEDULE 13G n/a (Amendment No. WuXi PharmaTech (Cayman) Inc (Name of Issuer) ADR 929352102 December 31, 2013 x o o * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures]
[SCHEDULE 13G n/a (Amendment No. WuXi PharmaTech (Cayman) Inc (Name of Issuer) ADR 929352102 December 31, 2013 x o o * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures]
[Joint Filing Agreement February 13, 2014 This Agreement may be executed in multiple counterparts, each of which shall constitute an original, one and the same instrument. Commonwealth Bank of Australia Margaret Taylor Company Secretary Colonial Holding Company Limited Michael Venter Director Commonwealth Insurance Holdings Limited Michael Venter Director Colonial First State Group Limited Michael Venter Director First State Investments (Hong] [Item 7 Information The securities being reported on by the reporting persons herein as parent holding companies are owned, or may be deemed to be beneficially owned as follows: Company Type of Company . First State Investment Management (UK) Limited IA (UK registered) First State Investments (Hong Kong) Limited IA (HK registered) EX-99.2 3 d675420dex992.htm EX-99.2] [USIP O C 13G Page 2 of 14 1. NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Commonwealth Bank of Australia 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP ¨ x (a) 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Australian Capital Territory, Commonwealth of Australia NUMBER OF SHARES BENEFICIALLY OWNED]
[Joint Filing Agreement February 13, 2014 This Agreement may be executed in multiple counterparts, each of which shall constitute an original, one and the same instrument. Commonwealth Bank of Australia Margaret Taylor Company Secretary Colonial Holding Company Limited Michael Venter Director Commonwealth Insurance Holdings Limited Michael Venter Director Colonial First State Group Limited Michael Venter Director First State Investments (Hong] [Item 7 Information The securities being reported on by the reporting persons herein as parent holding companies are owned, or may be deemed to be beneficially owned as follows: Company Type of Company . First State Investment Management (UK) Limited IA (UK registered) First State Investments (Hong Kong) Limited IA (HK registered) EX-99.2 3 d675420dex992.htm EX-99.2] [USIP O C 13G Page 2 of 14 1. NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Commonwealth Bank of Australia 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP ¨ x (a) 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Australian Capital Territory, Commonwealth of Australia NUMBER OF SHARES BENEFICIALLY OWNED]
[Sinovac Holds 2013 Annual General Meeting of Shareholders BEIJING, Aug. 21, 2013 /PRNewswire/ — Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today that it held its 2013 Annual General Meeting of Shareholders on Wednesday, August 21, 2013 at 9:00 a.m. Beijing Time. The required quorum, a majority of the common shares outstanding, was voted] [Sinovac to Participate in UBS Asia Healthcare CEO Summit in November 2013 BEIJING, Oct. 31, 2013 /PRNewswire/ — Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that Mr. Weidong Yin, Chairman, President and CEO of Sinovac, is invited to participate in UBS Asia Healthcare CEO Summit held in Hong Kong on November 1,] [Sinovac to Host Conference Call to Report Third Quarter 2013 Unaudited Financial Results EIJING, Nov. 4, 2013 /PRNewswire/ — Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2013, after market closes on Tuesday, November 12, 2013 EST. The Company] [Sinovac Receives Jiangsu Province Tender Award to Supply Inactivated Hepatitis Vaccine Healive(R) under Expanded Immunization Program BEIJING, Nov. 7, 2013 /PRNewswire/ — Sinovac Biotech Ltd. (SVA), a leading China-based vaccine manufacturer, announced today that it has been selected by the Jiangsu Centers for Disease Control and Prevention (Jiangsu CDC) to supply the Company's inactivated hepatitis A vaccine, Healive, under the] [Sinovac Reports Unaudited Third Quarter 2013 Financial Results - Conference call scheduled for Wednesday, November 13, 2013 at 8:00 AM EST - BEIJING, Nov. 12, 2013 /PRNewswire/ — Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited third quarter financial results for for the three and nine months ended September 30, 2013. 2013] []
